Motley Fool Premium
  1. Stocks
    2. /
  2. Knight Therapeutics (TSX: GUD)
    3. /

TSX:GUD (Knight Therapeutics)

About GUD

Knight Therapeutics, Inc. engages in the business of acquiring, in licensing, out-licensing, marketing, and commercializing pharmaceuticals products. The firm also focuses on building a portfolio of innovative products through in-licensing or acquiring product rights. The company was founded by Jonathan Ross Goodman on November 1, 2013 and is headquartered in Montréal, Canada.
Financial Market Data copyright © 2026 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

    • Knight Therapeutics (TSX: GUD) Latest News

    Dividend Stocks

    TFSA Investors: 2 Healthcare Stocks to Buy in May

    | Ambrose O'Callaghan

    It has been a wild 2020, but TFSA investors should target exciting healthcare stocks like Knight Therapeutics Inc. (TSX:GUD) to…

    Read more »

    Investing

    TFSA Investors: 2 Growth Stocks I’m Buying If the Market Selloff Gets Worse

    | Ambrose O'Callaghan

    During turbulent economic times, investors usually want to dial back risk and retreat to stable income vehicles. However, recent history…

    Read more »

    Investing

    Canada’s Most Undervalued Pharmaceutical Stock Is a Buy!

    | Nikhil Kumar

    Does the genius of CEO Jonathan Goodman of Knight Therapeutics Inc. (TSX:GUD) come for free?

    Read more »

    Investing

    Growth Investors: This Stock Could Easily Turn $10,000 Into $100,000

    | Nelson Smith

    Jonathan Goodman and Knight Therapeutics Inc. (TSX:GUD) could be the market's next great growth story. Are you willing to let…

    Read more »

    Investing

    Revealed: 5 Top Growth Picks From This Award-Winning Mutual Fund

    | Nelson Smith

    One of Canada's best mutual funds is investing in small-cap growth companies like Freshii Inc. (TSX:FRII), Aritzia Inc. (TSX:ATZ), and…

    Read more »

    Investing

    5 Reasons Why This Pharma Stock Is Poised for Takeoff

    | Kenrick Vassall

    Knight Therapeutics Inc. (TSX:GUD) has an effective low-risk strategy combined with one of the best balance sheets in the industry.

    Read more »

    The Motley Fool
    Investing

    Can Knight Therapeutics Inc. Repeat the Success of Paladin Labs?

    | Karen Thomas, MSc, CFA

    Knight Therapeutics Inc. (TSX:GUD) offers investors exposure to the lucrative specialty pharmaceutical market.

    Read more »